Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on gene therapies for eye diseases, reported its first-quarter financial results for 2024 and provided an update on its …
Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals Read More